Plus, news about Agenus, Gerresheimer and Oculis:
Nurix Therapeutics’ $175M offering: The protein degrader biotech upsized its stock sale, which it will use primarily to fund studies of its three early-stage clinical drug candidates, including two protein degraders for B-cell malignancies. Nurix’s shares $NRIX jumped by around 11% in the past month after the company announced research deal extensions with both Gilead and Sanofi, though the stock fell about 6% Friday morning. — Lei Lei Wu
Invivyd CEO leaves antibody biotech: David Hering, who succeeded former CEO Tillman Gerngross in 2022, was replaced by interim CEO Jeremy Gowler, per an SEC filing on Thursday. The Invivyd board is searching for a permanent successor to Hering. — Ayisha Sharma
Agenus shares Ph1 data for its checkpoint inhibitor combo: The combination of the company’s CTLA-4 antibody botensilimab and anti-PD-1 antibody balstilimab led to a 23% overall response rate and median overall survival of 21.2 months in 77 patients with microsatellite stable (MSS) colorectal cancer. This is a patient population that has historically seen limited efficacy from immunotherapy. A Phase 2 study is fully enrolled, and Agenus said it expects to submit an application to the FDA for its combination, which it calls bot/bal, in refractory MSS colorectal cancer this year. — Lei Lei Wu
Gerresheimer’s role in GLP-1 manufacturing: The German packaging company is working with the “only two players” in GLP-1s, with its sales driven by work with these companies, CEO Dietmar Siemssen said Thursday during its first quarter earning call, per an AlphaSense transcript. Novo Nordisk and Eli Lilly have been boosting their manufacturing footprint to address the extraordinary demand for their weight loss and diabetes drugs. — Anna Brown
Oculis’ $59M stock sale: The eye disease biotech sold shares to “new Icelandic institutional and existing investors,” which extends its runway to the second half of 2026. The company expects to report clinical data on its dry eye disease drug in the coming months, and it also expects to soon begin trading on the Nasdaq Iceland Main Market. — Lei Lei Wu